📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, totaling Rs 161 crore. The shares are being issued on a preferential basis to Cadamba Solutions Private Limited, a promoter group entity. This issue price represents a significant 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this capital infusion.
Key Highlights
Issuance of 1,000,000 equity shares at Rs 1,610 each, aggregating to Rs 161 crore
The issue price is 17.02% higher than the SEBI-calculated floor price of Rs 1,375.82
The entire allotment is directed to Cadamba Solutions Private Limited, part of the promoter group
Post-allotment, the allottee will hold a 3.65% stake in the company
Extraordinary General Meeting (EGM) set for March 29, 2026, with a record date of March 20, 2026
💼 Action for Investors
Investors should view this as a positive signal as the promoters are increasing their stake at a significant premium to the floor price. Monitor the company's subsequent announcements regarding the specific utilization of these funds for growth or debt reduction.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoters
Neogen Chemicals has announced an Extra Ordinary General Meeting (EGM) on March 29, 2026, to seek approval for a preferential issue of equity shares. The company plans to issue 10,00,000 shares to Cadamba Solutions Private Limited, a promoter group entity, at a price of Rs. 1,610 per share. This transaction will result in a total capital infusion of Rs. 161 crores into the company. The relevant date for determining the floor price was set as February 27, 2026, and the cut-off date for voting eligibility is March 20, 2026.
Key Highlights
Preferential allotment of 10,00,000 equity shares to promoter group entity Cadamba Solutions Private Limited.
Issue price fixed at Rs. 1,610 per share, including a premium of Rs. 1,600 per share.
Total fundraise amount of Rs. 161 crores to be received as 100% cash consideration.
EGM scheduled for March 29, 2026, with remote e-voting available from March 26 to March 28, 2026.
The capital infusion is subject to SEBI and stock exchange approvals following recent inter-se promoter transfers.
💼 Action for Investors
Investors should view this promoter-led capital infusion as a strong signal of confidence in the company's long-term growth. The non-debt funding will strengthen the balance sheet and support future expansion plans.
Neogen Chemicals to Raise ₹161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals has convened an Extra Ordinary General Meeting (EGM) on March 29, 2026, to approve a preferential issue of equity shares. The company intends to issue 10,00,000 shares to Cadamba Solutions Private Limited, a member of the promoter group. The shares are priced at ₹1,610 each, including a premium of ₹1,600, resulting in a total fund infusion of ₹161 crore. This capital injection by the promoters indicates strong internal confidence in the company's future growth prospects.
Key Highlights
Issuance of 10,00,000 equity shares at a fixed price of ₹1,610 per share.
Total capital raise amounting to ₹161 crore from promoter group entity Cadamba Solutions Private Limited.
Relevant date for floor price determination set as February 27, 2026, in accordance with SEBI ICDR regulations.
EGM scheduled for March 29, 2026, to seek shareholder approval via special resolution.
The allotment is subject to a lock-in period as per SEBI regulations and requires specific regulatory exemptions due to prior inter-se transfers.
💼 Action for Investors
Investors should view the promoter's capital infusion at a significant premium as a positive signal of long-term commitment. Monitor the EGM results and subsequent disclosures regarding the specific utilization of these funds for expansion or debt reduction.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group
Neogen Chemicals' board has approved the issuance of 10 lakh equity shares at a price of Rs 1,610 per share, aggregating to Rs 161 crore. The shares are being issued to Cadamba Solutions Private Limited, a promoter group entity, which will hold a 3.65% stake post-allotment. Significantly, the issue price is at a 17.02% premium over the regulatory floor price of Rs 1,375.82. An Extra Ordinary General Meeting (EGM) is scheduled for March 29, 2026, to obtain shareholder approval for the transaction.
Key Highlights
Issuance of 10,00,000 equity shares at Rs 1,610 per share, totaling Rs 161 crore
Issue price is 17.02% higher than the SEBI-mandated floor price of Rs 1,375.82
Allottee is Cadamba Solutions Private Limited, a member of the promoter group
Post-allotment, the allottee will hold a 3.65% stake in the company
EGM for shareholder approval is set for March 29, 2026, with a record date of March 20, 2026
💼 Action for Investors
Investors should take confidence from the promoter group's decision to infuse capital at a significant premium to the floor price. This move strengthens the balance sheet and indicates strong internal backing for the company's growth prospects.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue at Rs 1,610 Per Share
Neogen Chemicals has approved a preferential issue of 10 lakh equity shares to Cadamba Solutions Private Limited, a promoter group entity. The issue is priced at Rs 1,610 per share, which is a significant 17.02% premium over the SEBI-mandated floor price of Rs 1,375.82. This move will result in a total capital infusion of Rs 161 crore into the company. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to seek shareholder approval for this transaction.
Key Highlights
Issuance of 10,00,000 equity shares at a price of Rs 1,610 per share
Total fundraise amount aggregates to Rs 161 crore
Issue price is 17.02% higher than the regulatory floor price of Rs 1,375.82
Allottee is Cadamba Solutions Private Limited, belonging to the Promoter Group
Post-allotment, the allottee will hold a 3.65% stake in the company
💼 Action for Investors
Investors should take note of the promoter group's commitment to infuse capital at a premium to the floor price, which signals strong internal confidence. Monitor the EGM outcome and subsequent updates on how the capital will be deployed for growth initiatives.
Neogen Chemicals to Raise Rs 161 Crore via Preferential Issue to Promoter Group at Rs 1,610/Share
Neogen Chemicals' board has approved the issuance of 10 lakh equity shares to Cadamba Solutions Private Limited, a promoter group entity, on a preferential basis. The shares are priced at Rs 1,610 each, representing a significant 17.02% premium over the SEBI-mandated floor price of Rs 1,375.82. This capital infusion will aggregate to Rs 161 crore and result in the allottee holding a 3.65% stake in the company post-allotment. An Extraordinary General Meeting (EGM) is scheduled for March 29, 2026, to obtain shareholder approval for the transaction.
Key Highlights
Issuance of 10,00,000 equity shares at a price of Rs 1,610 per share (including Rs 1,600 premium).
Total fundraise amount aggregates to Rs 161 crore from promoter group entity Cadamba Solutions Private Limited.
Issue price is 17.02% higher than the regulatory floor price of Rs 1,375.82.
Post-allotment, the promoter group entity will hold a 3.65% stake in the company.
EGM for shareholder approval is set for March 29, 2026, with a record date of March 20, 2026.
💼 Action for Investors
Investors should view this as a strong signal of promoter confidence, as the capital is being infused at a premium to the floor price. The funds will likely strengthen the balance sheet for future expansion or debt management.
Neogen Chemicals Q3 FY26 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Promoter Fundraise
Neogen Chemicals reported a 9% YoY revenue growth to ₹220 crore in Q3 FY26, driven by a 35% surge in the inorganic chemicals segment. While gross margins expanded by 150 bps, PAT remained suppressed at ₹4 crore due to high interest costs and transient expenses related to the Neogen Ionics ramp-up. The company is on track to commission its rebuilt Dahej plant in Q1 FY27 and has secured a ₹150 crore preferential equity infusion from promoters. Additionally, a strategic JV with Japan's Morita Investment is progressing with a $20 million incoming investment for battery material production.
Key Highlights
Q3 FY26 revenue grew 9% YoY to ₹220 crore, with inorganic chemicals growing 35% to ₹33 crore.
Net profit stood at ₹4 crore, impacted by ₹1,175 crore consolidated net debt and front-loaded expansion costs.
Board approved a ₹150 crore preferential share issue to promoters to provide financial flexibility for growth.
Insurance claim of ₹251.12 crore is pending, with ₹60 crore expected immediately and the bulk by March 2026.
Battery materials division (Neogen Ionics) contributed ₹12 crore; Pakhajan project on track for FY27 production.
💼 Action for Investors
Investors should monitor the timely commissioning of the Dahej and Pakhajan facilities and the receipt of insurance claims to deleverage the balance sheet. The promoter's ₹150 crore infusion is a positive signal of confidence despite current margin pressures from expansion.
Neogen Chemicals Receives Rs 60 Cr Insurance Payout; Total Recovery Reaches Rs 140 Cr
Neogen Chemicals has received a third on-account insurance payment of Rs 60 Crore following the fire incident at its Dahej SEZ facility in March 2025, bringing total recoveries to Rs 140 Crore. The company has recognized a consolidated loss of Rs 362.90 Crore but expects to recover Rs 348.82 Crore through insurance, resulting in a net impact of only Rs 14.08 Crore. While the affected MPP3 plant remains suspended, a replacement facility is scheduled for commissioning in Q1 FY27. To mitigate earnings impact, the company has shifted critical production to other sites and is leveraging its Patancheru plant expansion.
Key Highlights
Received Rs 60 Crore as the third on-account insurance payment, totaling Rs 140 Crore to date.
Consolidated loss recognized at Rs 362.90 Crore against an expected insurance recovery of Rs 348.82 Crore.
Net financial impact on the company estimated at Rs 14.08 Crore on a consolidated basis.
Replacement plant construction is underway with a target commissioning date of Q1 FY27.
Production of critical specialty products shifted to other sites and Patancheru plant to minimize earnings impact.
💼 Action for Investors
Investors should monitor the execution timeline for the replacement plant scheduled for Q1 FY27 and the company's ability to maintain margins while operating from alternative sites. The steady inflow of insurance claims is a positive sign for liquidity and asset recovery.
Neogen Chemicals Q3 FY26 Revenue up 9% to ₹220 Cr; PAT drops 63% on Transitory Costs
Neogen Chemicals reported a 9% YoY growth in consolidated revenue to ₹220 crore for Q3 FY26, supported by steady demand in organic and inorganic chemicals. However, consolidated PAT plummeted 63% to ₹3.7 crore, primarily due to elevated interest costs (₹21.5 crore), higher insurance premiums following a fire incident, and pre-operative expenses for the battery chemicals division. The company is executing a massive ₹1,500 crore CAPEX plan for Neogen Ionics, targeting peak revenues of up to ₹2,950 crore by FY29. To support this growth, the Board has approved a ₹150 crore preferential issue to the Promoter Group.
Key Highlights
Consolidated Revenue increased 9% YoY to ₹220 crore, while Standalone Revenue grew 8% to ₹215.6 crore.
Consolidated PAT declined 63% YoY to ₹3.7 crore due to a 60% surge in interest costs and fire-related operational headwinds.
Neogen Ionics (Battery Chemicals) reported ₹12 crore in revenue for Q3 FY26, with the Pakhajan Greenfield project on track for H1 FY27.
The company has received ₹83.48 crore in insurance claims so far, with a net receivable of ₹251.12 crore still pending.
Board approved a ₹150 crore preferential equity issue to promoters to reinforce the company's capital base for expansion.
💼 Action for Investors
Investors should focus on the commissioning timelines of the Pakhajan plant in FY27 and the normalization of interest costs as insurance payouts are received. While current profitability is under pressure, the long-term growth trajectory in the battery chemicals segment and promoter backing remain key positive triggers.
Neogen Chemicals Q3 Revenue Up 9% to ₹220 Cr; Plans ₹150 Cr Fundraise via Promoters
Neogen Chemicals reported a 9% YoY revenue growth to INR 220 crore in Q3 FY26, driven by volume growth in organic and inorganic chemicals. While consolidated PAT rose 63% to INR 4 crore, profitability was weighed down by finance costs and transitory expenses related to the Dahej plant fire and battery chemical expansions. The company is raising INR 150 crore from promoters to fuel growth and has formed a strategic JV with Japan's Morita Investment for lithium salt production. Progress on the Pakhajan Greenfield project remains on track for commissioning in FY27.
Key Highlights
Consolidated Revenue grew 9% YoY to INR 220 crore; Standalone PAT stood at INR 9 crore
Board approved raising up to INR 150 crore through a preferential issue to the Promoter Group
Received INR 83.48 crore in insurance claims for the Dahej fire; net receivable remains at INR 251.12 crore
Formed an 80:20 JV with Japan’s Morita Investment for global LiPF6 salt production
Pakhajan Electrolyte plant nearing mechanical completion with commercial production expected in H1 FY27
💼 Action for Investors
Investors should monitor the progress of the Pakhajan facility and the recovery of insurance claims, which are expected to normalize interest costs. The promoter-led fundraise and Japanese JV signal strong long-term confidence in the battery materials segment.
Neogen Chemicals Q3 FY26 Revenue Up 9% to ₹220 Cr; PAT Drops 63% on Fire-Related Costs
Neogen Chemicals reported a 9% YoY revenue growth in Q3 FY26, reaching ₹220 crore, driven by volume growth in organic and inorganic chemicals. However, net profit (PAT) plummeted by 63% to ₹3.7 crore due to transitory costs from a Dahej plant fire, higher interest expenses, and pre-operative spends for the battery chemicals division. The company is aggressively expanding its battery materials segment with a ₹1,500 crore capex plan and a new JV with Japan's Morita Investment for LiPF6 salt. Management expects insurance recoveries in FY27 and significant revenue contributions from the Pakhajan project starting H1 FY27.
Key Highlights
Consolidated Revenue grew 9% YoY to ₹220 crore in Q3 FY26, while 9M FY26 revenue reached ₹615.4 crore.
Net Profit (PAT) declined sharply by 63% YoY to ₹3.7 crore, impacted by ₹21.5 crore interest costs and fire-related overheads.
Board approved a ₹150 crore preferential equity issue to promoters to fund growth initiatives.
Finalized an 80:20 JV with Japan's Morita Investment for global LiPF6 electrolyte salt production.
Total planned Capex of ₹1,500 crore targets a peak revenue potential of up to ₹2,950 crore by FY29.
💼 Action for Investors
Investors should monitor the commissioning of the Pakhajan plant in H1 FY27 and the recovery of insurance claims, which are critical for margin normalization. The stock remains a long-term play on the EV battery supply chain, though near-term profitability is under pressure from high finance costs.
Neogen Chemicals Q3 Net Profit Drops 39% YoY to ₹8.77 Cr Despite 7.6% Revenue Growth
Neogen Chemicals reported a mixed performance for Q3 FY26, with revenue from operations growing 7.6% YoY to ₹215.60 crore. However, net profit saw a sharp decline of 39.1% YoY to ₹8.77 crore, primarily driven by a 74.8% surge in finance costs which reached ₹22.85 crore. The company is still recovering from the March 2025 fire at its Dahej SEZ plant, having received ₹80 crore in insurance payments to date. While operating margins remained stable at 17%, the increased debt burden and interest expenses are significantly weighing on the bottom-line profitability.
Key Highlights
Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.
Net profit declined to ₹8.77 crore compared to ₹14.41 crore in the corresponding quarter of the previous year.
Finance costs spiked significantly to ₹22.85 crore from ₹13.07 crore YoY, reflecting higher borrowing costs.
The company has received ₹80 crore in on-account insurance payments for the Dahej plant fire loss as of December 2025.
Operating margin stood at 17%, while the net profit margin contracted to 4% from 7% YoY.
💼 Action for Investors
Investors should be cautious as rising finance costs and debt levels are eroding the benefits of revenue growth. Monitor the progress of the remaining insurance claims and the company's ability to deleverage its balance sheet in the coming quarters.
Neogen Chemicals Q3 Profit Drops to ₹8.77 Cr; Board Approves Fundraise via Preferential Issue
Neogen Chemicals reported a 39% YoY decline in net profit to ₹8.77 crore for Q3 FY26, despite a 7.5% increase in revenue to ₹215.60 crore. The company's board has granted in-principle approval for a fundraise through a preferential issue of equity shares to bolster its financial position. Operations are still recovering from a significant fire at the Dahej SEZ plant in March 2025, with ₹80 crore in insurance payments received to date against a total claim of ₹334.60 crore. Elevated finance costs of ₹22.85 crore significantly weighed on the quarterly performance.
Key Highlights
Revenue from operations increased 7.5% YoY to ₹215.60 crore in Q3 FY26.
Net Profit (PAT) fell to ₹8.77 crore from ₹14.41 crore in the previous year's corresponding quarter.
Board approved raising funds through a preferential issue of equity shares.
Received ₹80 crore in insurance on-account payments against a total fire-related claim of ₹334.60 crore.
Finance costs surged to ₹22.85 crore, up from ₹13.07 crore in Q3 FY25.
💼 Action for Investors
Investors should monitor the pricing and size of the upcoming preferential issue as it will result in equity dilution. While the revenue growth is positive, the recovery of the remaining insurance claim and management's ability to control rising finance costs are critical for margin improvement.
Neogen Chemicals Q3 FY26 Revenue up 7.6% YoY to ₹215.6 Cr; PAT Declines 39% on Higher Finance Costs
Neogen Chemicals reported a modest revenue growth of 7.6% YoY to ₹215.60 crore for the quarter ended December 31, 2025. However, Net Profit (PAT) saw a significant decline of 39.1% YoY, dropping to ₹8.77 crore from ₹14.41 crore in the previous year's corresponding quarter. This bottom-line pressure is primarily attributed to a 74.8% surge in finance costs, which rose to ₹22.85 crore. The company is still managing the aftermath of a major fire at its Dahej plant from March 2025, having received ₹80 crore in insurance payments during the current fiscal year so far.
Key Highlights
Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.
Net Profit (PAT) fell to ₹8.77 crore in Q3 FY26 compared to ₹14.41 crore in Q3 FY25.
Finance costs spiked significantly to ₹22.85 crore in Q3 FY26 from ₹13.07 crore in Q3 FY25.
Received ₹80 crore as on-account insurance payments for the Dahej plant fire incident during the nine months ended Dec 2025.
Inventory turnover days increased to 197 days, up from 162 days in the preceding quarter (Sep 2025).
💼 Action for Investors
Investors should monitor the rising finance costs and debt levels, as the debt-to-equity ratio stands at 0.89. While revenue growth is steady, the sharp decline in profitability and increased inventory days suggest operational and financial headwinds that require caution.
Neogen Chemicals Q3 FY26 Revenue Up 7.6% YoY to ₹215.6 Cr; PAT Declines 39% to ₹8.77 Cr
Neogen Chemicals reported a 7.6% YoY revenue growth to ₹215.60 crore for the quarter ended December 31, 2025. However, net profit declined significantly by 39% YoY to ₹8.77 crore, largely due to a sharp 74.8% increase in finance costs which reached ₹22.85 crore. The company is still managing the aftermath of a major fire at its Dahej plant from March 2025, having received ₹80 crore in insurance payments to date against a total claim of ₹334.60 crore. While operating margins remained steady at 17%, the net profit margin contracted to 4% due to the interest burden.
Key Highlights
Revenue from operations increased to ₹215.60 crore in Q3 FY26 from ₹200.41 crore in Q3 FY25.
Net Profit (PAT) dropped to ₹8.77 crore, down from ₹14.41 crore in the same quarter last year.
Finance costs surged to ₹22.85 crore compared to ₹13.07 crore in the previous year's quarter.
Received ₹80 crore in insurance payments during the nine months ended Dec 2025 for the Dahej plant fire.
Debt-to-Equity ratio stood at 0.89x with an Interest Service Coverage Ratio (trailing 12 months) of 2.19.
💼 Action for Investors
Investors should exercise caution as rising finance costs and debt levels are significantly impacting the bottom line despite revenue growth. Monitor the full restoration of the Dahej plant and the final settlement of the remaining insurance claims as key recovery catalysts.
Neogen Chemicals Promoter Transfers 21.9% Stake to Family Trusts via Gift
Haridas Thakarshi Kanani, Promoter and Chairman Emeritus of Neogen Chemicals, has transferred 57,78,500 equity shares, representing 21.90% of the company's paid-up capital. The transfer was executed as a gift through off-market transactions to the Haridas Kanani Family Trust and H T Kanani Family Trust. This internal restructuring follows a SEBI exemption order dated December 30, 2025, for estate planning purposes. While the individual promoter's direct holding decreased to 1.42%, the overall promoter group's control remains unchanged.
Key Highlights
Promoter Haridas Thakarshi Kanani gifted 57,78,500 shares (21.90% stake) to family trusts
Haridas Kanani Family Trust acquired 52,76,500 shares, representing approximately 20% stake
H T Kanani Family Trust acquired 5,02,000 shares, representing approximately 1.9% stake
Transaction conducted as an off-market inter-se transfer following a SEBI Exemption Order
Individual promoter's direct stake reduced from 23.33% to 1.42% post-transfer
💼 Action for Investors
This is a routine internal restructuring for estate planning and does not involve a market sale or change in management control. Investors should treat this as a neutral administrative update with no impact on company fundamentals.
Neogen Chemicals Promoter Gifts 21.9% Stake to Family Trusts in Inter-se Transfer
Haridas Thakarshi Kanani, the Promoter and Chairman Emeritus of Neogen Chemicals, has transferred 57,78,500 equity shares, representing 21.90% of the company's paid-up capital. This transfer was executed as a gift through off-market transactions to two family trusts: Haridas Kanani Family Trust and H T Kanani Family Trust. The move follows a SEBI exemption order and is part of internal succession planning within the promoter group. There is no change in the total promoter group holding or any impact on market liquidity as these were off-market transfers.
Key Highlights
Promoter Haridas Thakarshi Kanani gifted 57,78,500 shares (21.90% stake) via off-market transactions
Haridas Kanani Family Trust acquired 52,76,500 shares, representing approximately 20% stake
H T Kanani Family Trust acquired 5,02,000 shares, representing approximately 1.9% stake
Haridas Thakarshi Kanani's direct holding reduced from 23.33% to 1.42% post-transaction
Transactions were executed on December 31, 2025, following a SEBI exemption order dated December 30, 2025
💼 Action for Investors
Investors should treat this as a neutral administrative event related to promoter succession planning. Since the shares were gifted to family trusts off-market, there is no impact on the company's operations or stock market supply.
Neogen Chemicals Promoter Gifts 21.90% Stake to Family Trusts in Off-Market Transfer
Haridas Thakarshi Kanani, the Promoter and Chairman Emeritus of Neogen Chemicals, has transferred 57,78,500 equity shares, representing 21.90% of the company's paid-up capital. The transfer was executed as an off-market gift to two entities: Haridas Kanani Family Trust (52,76,500 shares) and H T Kanani Family Trust (5,02,000 shares). This is an inter-se transfer within the promoter group for estate planning purposes, conducted under a SEBI Exemption Order. The transaction does not result in any change in the overall promoter group shareholding or a sale of shares in the open market.
Key Highlights
Promoter Haridas Thakarshi Kanani gifted 57,78,500 shares (21.90% stake) via off-market transactions.
Haridas Kanani Family Trust acquired 52,76,500 shares, becoming a major promoter group entity.
H T Kanani Family Trust acquired 5,02,000 shares as part of the same restructuring.
Haridas Thakarshi Kanani's individual stake reduced from 23.33% to 1.42% post-transfer.
The transfer was executed on December 31, 2025, following a SEBI Exemption Order dated December 30, 2025.
💼 Action for Investors
Investors should treat this as a routine internal restructuring for estate planning with no impact on company fundamentals or market liquidity. No action is required as the overall promoter control remains unchanged.
Neogen Chemicals Promoter Gifts 21.9% Stake to Family Trusts for Succession Planning
Haridas Thakarshi Kanani, the Promoter and Chairman Emeritus of Neogen Chemicals, has transferred 57,78,500 equity shares, representing 21.90% of the company's paid-up capital. The transfer was executed as a gift through an off-market transaction on December 31, 2025, to two family trusts: Haridas Kanani Family Trust and H T Kanani Family Trust. This inter-se transfer among the promoter group follows a SEBI exemption order and is intended for estate planning. Post-transaction, the direct holding of Haridas Thakarshi Kanani has decreased from 23.33% to approximately 1.42%, while the trusts are now classified as promoter group shareholders.
Key Highlights
Transfer of 57,78,500 equity shares representing 21.90% of the total paid-up capital.
Transaction conducted as a gift (off-market) to Haridas Kanani Family Trust and H T Kanani Family Trust.
Haridas Kanani Family Trust acquired 52,76,500 shares, roughly 20% of the company.
Haridas Thakarshi Kanani's direct stake reduced from 23.33% to 1.42% post-transfer.
The restructuring follows SEBI Exemption Order WTM/KCV/CFD/17/2025-26 dated December 30, 2025.
💼 Action for Investors
This is an internal promoter group restructuring for succession planning and does not involve a market sale or change in management control. Investors should treat this as a neutral administrative event with no impact on the company's fundamentals or share liquidity.